中藥配方顆粒規範出台，培力農本方（1498.HK）佔據行業制高點
11月16日，國家中醫藥管理局發佈了《關於規範醫療機構中藥配方顆粒臨牀使用的通知》，這是中藥配方顆粒試點工作在11月1日正式結束後的又一重磅文件。
本次發佈的《規範》中，提出了中藥配方顆粒銷售場所的具體要求，文件指出：“各級衞生健康和中醫藥主管部門要規範醫療機構中藥配方顆粒使用，經審批或備案能夠提供中醫藥服務的醫療機構方可使用中藥配方顆粒。”
對比已結束的試點工作來看，在銷售場所方面此前的規定“中藥配方顆粒不得在醫療機構以外銷售”，中藥配方顆粒只能在二級及以上中醫醫院（綜合醫院）銷售，這也導致了中藥配方顆粒以往的銷售渠道較為有限，在此限制下藥企的中藥配方顆粒產品普遍難以快速放量。
本次《規範》的出台，對“醫療機構”這一詞加以更明確的限定，接下來符合一定要求的醫療機構都可以銷售中藥配方顆粒，相比之下《規範》增加了中藥配方顆粒的銷售渠道，大幅拓寬中藥配方顆粒的銷售範圍。
值得注意的是，在生產濃縮中藥配方顆粒企業中，培力農本方（1498.HK）這家中國香港中藥製造商，在香港及內地擁有近30間連鎖中醫診所，目前已穩居中國香港濃縮中藥配方顆粒產品市場的領導地位,擁有高達83%的市場份額。特別是在中國大陸，公司的濃縮中藥配方顆粒表現尤為不俗，該項業務所帶來的收入正快速增長，目前佔總營業收入的比重已過半。
可以預見，未來隨着《規範》的落地，無論是在中國香港還是中國大陸，中藥配方顆粒的可及性都將快速提高。對於核心產品正是中藥配方顆粒的培力農本方而言，該項政策的實施無疑是重磅利好，公司也將搶佔中藥配方顆粒行業的市場增量。
此外，《規範》還明確了中藥配方顆粒監管的各項細則，在加強對中藥配方顆粒採購、臨牀使用等環節管理，杜絕中藥配方顆粒統方、收受回扣等措施及落實情況納入醫院巡查重點內容等方面作出關鍵指示，將促進中藥配方顆粒行業健康、有序地發展。
而培力農本方近年來運用現代化技術實現線上營銷、開設標準化的農本方®中醫診所等，不斷規範化中醫診療流程，提供更透明的產品價格與更優質的服務，符合國家對中藥配方顆粒的政策要求。
總體來説，本次《規範》的發佈，是國家支持中藥配方顆粒良性發展的一大里程碑。作為該領域內的龍頭企業，培力農本方將成為第一批政策獲益者，其主營業務中藥配方顆粒的銷量有望迅速增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
